• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATX 0.00% 6.2¢

AMPLIA THERAPEUTICS LIMITED - Announcements

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development... Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company’s pipeline includes AMP945 and AMP886. AMP945 is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Announcements


ATX Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE30/04/24 download Created with Sketch. 304.9KB
ATX Entitlement Offer - Offer Booklet24/04/24 download Created with Sketch. 6.4MB
ATX Proposed issue of securities - ATX16/04/24 download Created with Sketch. 22.05KB
ATX Entitlement Offer Cleansing Statement16/04/24 download Created with Sketch. 192.21KB
ATX Rights Issue Investor Slide DeckPRICE SENSITIVE16/04/24 download Created with Sketch. 5.96MB
ATX Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27PRICE SENSITIVE16/04/24 download Created with Sketch. 167.5KB
ATX Trading HaltPRICE SENSITIVE12/04/24 download Created with Sketch. 209.46KB
ATX AACR Conference Presentation10/04/24 download Created with Sketch. 834.44KB
ATX Update on ACCENT Trial in Pancreatic CancerPRICE SENSITIVE27/03/24 download Created with Sketch. 169.3KB
ATX Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE30/01/24 download Created with Sketch. 393.35KB
ATX FDA Clearance Amplia's IND for Pancreatic Cancer Trial in USPRICE SENSITIVE18/01/24 download Created with Sketch. 162.54KB
ATX Trading HaltPRICE SENSITIVE17/01/24 download Created with Sketch. 551.88KB
ATX Pause in TradingPRICE SENSITIVE17/01/24 download Created with Sketch. 114.79KB
ATX Amplia Reports First Patient Dosing In Phase 2a Accent TrialPRICE SENSITIVE17/01/24 download Created with Sketch. 169.03KB
ATX Change of Director's Interest Notice - Dr Warwick Tong02/01/24 download Created with Sketch. 348.85KB
ATX Change of Director's Interest Notice - Dr Chris Burns02/01/24 download Created with Sketch. 348KB
ATX Change of Director's Interest Notice - Dr Robert Peach02/01/24 download Created with Sketch. 351.14KB
ATX Change of Director's Interest Notice - Jane Bell02/01/24 download Created with Sketch. 323.98KB
ATX Notification of cessation of securities - ATX02/01/24 download Created with Sketch. 21.65KB
ATX Application for quotation of securities - ATX02/01/24 download Created with Sketch. 25.05KB
ATX Approval to Initiate Phase2 Pancreatic Cancer Trial in KoreaPRICE SENSITIVE04/12/23 download Created with Sketch. 166.59KB
ATX Appendix 4D and Financial Report Half Year ended 30 Sep 23PRICE SENSITIVE21/11/23 download Created with Sketch. 655.63KB
ATX Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE31/10/23 download Created with Sketch. 301.06KB
ATX Promising Clinical Data 1b ACCENT Trial in Pancreatic CancerPRICE SENSITIVE30/10/23 download Created with Sketch. 179.92KB
ATX Amplia Receives R&D Tax Rebate Totalling $ 2.4 MillionPRICE SENSITIVE19/10/23 download Created with Sketch. 109.36KB
ATX AACR Ovarian Cancer Conference PresentationPRICE SENSITIVE09/10/23 download Created with Sketch. 5.12MB
ATX AACR Pancreatic Cancer Conference Presentation29/09/23 download Created with Sketch. 14.3MB
ATX New Chief Financial Officer Mr Tim Luscombe25/09/23 download Created with Sketch. 106.37KB
ATX Notification of cessation of securities - ATX04/09/23 download Created with Sketch. 21.69KB
ATX Notification of cessation of securities - ATX01/09/23 download Created with Sketch. 21.71KB
ATX Change of Director's Interest Notice - Dr Robert Peach01/09/23 download Created with Sketch. 351.61KB
ATX Change of Director's Interest Notice - Dr Christopher Burns29/08/23 download Created with Sketch. 351.31KB
ATX Notification regarding unquoted securities - ATX29/08/23 download Created with Sketch. 29.02KB
ATX Results of Annual General Meeting24/08/23 download Created with Sketch. 291.34KB
ATX CEO and MD Presentation to Annual General Meeting24/08/23 download Created with Sketch. 2.87MB
ATX ACCENT Trial Recruitment Update02/08/23 download Created with Sketch. 140.26KB
ATX ATX Quarterly Activities and Cashflow Reports - June 23 QtrPRICE SENSITIVE31/07/23 download Created with Sketch. 307.66KB
ATX Notice of Annual General Meeting/Proxy Form21/07/23 download Created with Sketch. 547.44KB
ATX ATX - Shareholder Newsletter July 202320/07/23 download Created with Sketch. 5.49MB
ATX Application for quotation of securities - ATX12/07/23 download Created with Sketch. 24.84KB
ATX AMP945 International Nonproprietary Name Narmafotinib21/06/23 download Created with Sketch. 104.84KB
ATX Amplia AGM to be held Thursday 24 August 202319/06/23 download Created with Sketch. 121.36KB
ATX Key to Corporate Governance Disclosures31/05/23 download Created with Sketch. 292.87KB
ATX 2023 Corporate Governance Statement30/05/23 download Created with Sketch. 418.65KB
ATX Annual Report to ShareholdersPRICE SENSITIVE30/05/23 download Created with Sketch. 5.52MB
ATX AMP945 and FOLFIRINOX active in model of Pancreatic CancerPRICE SENSITIVE29/05/23 download Created with Sketch. 197.6KB
ATX Grant to collaborate with CSIRO Supplementary AnnouncementPRICE SENSITIVE23/05/23 download Created with Sketch. 134.41KB
ATX Amplia receives grant to collaborate with CSIROPRICE SENSITIVE22/05/23 download Created with Sketch. 130.74KB
ATX ACCENT Trial Recruitment ProgressPRICE SENSITIVE09/05/23 download Created with Sketch. 161.79KB
ATX Quarterly Activities and Cashflow Reports - March 23 QtrPRICE SENSITIVE26/04/23 download Created with Sketch. 275.01KB
ATX First Patient Recruited to Cohort 3 of ACCENT TrialPRICE SENSITIVE19/04/23 download Created with Sketch. 132.31KB
ATX Dose Escalation Approved in ACCENT Clinical Trial of AMP945PRICE SENSITIVE11/04/23 download Created with Sketch. 160.83KB
ATX ACCENT Trial Recruitment ProgressPRICE SENSITIVE28/02/23 download Created with Sketch. 133.69KB
ATX ATX - US Conference Presentation23/02/23 download Created with Sketch. 1.64MB
ATX AmpliaTherapeutics - Lorne Cancer Conference Presentation09/02/23 download Created with Sketch. 713.45KB
ATX First Patient Recruited to Cohort 2 of Accent TrialPRICE SENSITIVE01/02/23 download Created with Sketch. 131.5KB
ATX Quarterly Activities and Cashflow Reports - December 2022PRICE SENSITIVE30/01/23 download Created with Sketch. 340.02KB
ATX Dose Escalation Approved in ACCENT Clinical Trial of AMP945PRICE SENSITIVE11/01/23 download Created with Sketch. 165.61KB
ATX Letter to Shareholders End of Year Summary and 2023 PlansPRICE SENSITIVE20/12/22 download Created with Sketch. 3.21MB
ATX Final Director's Interest Notice - Dr. John Lambert01/12/22 download Created with Sketch. 375.23KB
ATX ACCENT Trial Recruitment ProgressPRICE SENSITIVE29/11/22 download Created with Sketch. 103.3KB
ATX Appendix 4D and Financial Report Half Year ended 30 Sep 22PRICE SENSITIVE18/11/22 download Created with Sketch. 2.23MB
ATX Amplia Appoints Dr Christopher Burns CEO & Managing DirectorPRICE SENSITIVE07/11/22 download Created with Sketch. 132.58KB
ATX Quarterly Activities and Cashflow Reports - Sep 2022 QtrPRICE SENSITIVE28/10/22 download Created with Sketch. 503.17KB
ATX Notification regarding unquoted securities - ATX10/10/22 download Created with Sketch. 28.37KB
ATX AMP886 Activity in Acute Myeloid LeukemiaPRICE SENSITIVE03/10/22 download Created with Sketch. 238.68KB
ATX AACR Conference Presentation14/09/22 download Created with Sketch. 848.81KB
ATX CEO ResignationPRICE SENSITIVE12/09/22 download Created with Sketch. 103.1KB
ATX Notification regarding unquoted securities - ATX07/09/22 download Created with Sketch. 29.46KB
ATX Change of Director's Interest Notice - Dr. Warwick Tong07/09/22 download Created with Sketch. 347.59KB
ATX Change of Director's Interest Notice - Dr. Robert Peach07/09/22 download Created with Sketch. 350.91KB
ATX Change of Director's Interest Notice - Dr. Christopher Burns07/09/22 download Created with Sketch. 346.2KB
ATX Change of Director's Interest Notice - Mrs. Jane Bell07/09/22 download Created with Sketch. 285.71KB
ATX Change of Director's Interest Notice - Dr. John Lambert06/09/22 download Created with Sketch. 365.18KB
ATX Notification of cessation of securities - ATX02/09/22 download Created with Sketch. 21.68KB
ATX Amplia Receives $1.8m R&D Tax IncentivePRICE SENSITIVE31/08/22 download Created with Sketch. 104.17KB
ATX Results of Annual General Meeting25/08/22 download Created with Sketch. 341.43KB
ATX CEO & Managing Director Presentation to AGMPRICE SENSITIVE25/08/22 download Created with Sketch. 5.94MB
ATX Annual General Meeting - ESOP and New Constitution17/08/22 download Created with Sketch. 165.68KB
ATX Employee Security Ownership Plan17/08/22 download Created with Sketch. 382.88KB
ATX Change of Director's Interest Notice - Dr. Warwick Tong04/08/22 download Created with Sketch. 345.52KB
ATX First Patient Recruited to ACCENT Trial in Pancreatic CancerPRICE SENSITIVE02/08/22 download Created with Sketch. 132.49KB
ATX Quarterly Activities and Cashflow Reports - June 2022 QtrPRICE SENSITIVE28/07/22 download Created with Sketch. 371.69KB
ATX Presentation at Major Pancreatic Cancer Conference25/07/22 download Created with Sketch. 153.78KB
ATX Notice of Annual General Meeting/Proxy - YE 31 March 202222/07/22 download Created with Sketch. 591.2KB
ATX Change of Director's Interest Notice - Dr. Chistopher Burns07/07/22 download Created with Sketch. 341.79KB
ATX Change of Director's Interest Notice - Dr. Robert Peach07/07/22 download Created with Sketch. 276.74KB
ATX Change of Director's Interest Notice - Dr. John Lambert07/07/22 download Created with Sketch. 467.75KB
ATX Change of Director's Interest Notice - Dr. Warwick Tong07/07/22 download Created with Sketch. 402.32KB
ATX Notification of cessation of securities - ATX05/07/22 download Created with Sketch. 21.69KB
ATX Application for quotation of securities - ATX30/06/22 download Created with Sketch. 24.91KB
ATX Annual General Meeting to be held Thursday 25 August 202229/06/22 download Created with Sketch. 118.42KB
ATX Registered Office and Principal Place of Business24/06/22 download Created with Sketch. 127.54KB
ATX Notification of Expiry of Unlisted Options09/06/22 download Created with Sketch. 210.42KB
ATX Application for quotation of securities - ATX09/06/22 download Created with Sketch. 24.91KB
ATX AMP945 Shows Efficacy in Model of Lung FibrosisPRICE SENSITIVE02/06/22 download Created with Sketch. 182.84KB
ATX App 4G - Key to Corporate Governance Disclosures30/05/22 download Created with Sketch. 368.09KB
ATX 2022 Corporate Governance Statement30/05/22 download Created with Sketch. 396.46KB
ATX Preliminary Final Report and Annual Report YE 31 March 2022PRICE SENSITIVE30/05/22 download Created with Sketch. 2.92MB
ATX Amplia Receives Second Ethics Clearance for Phase 2 TrialPRICE SENSITIVE13/05/22 download Created with Sketch. 158.42KB
ATX Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24PRICE SENSITIVE download Created with Sketch. 304.9KB
ATX Entitlement Offer - Offer Booklet
24/04/24 download Created with Sketch. 6.4MB
ATX Proposed issue of securities - ATX
16/04/24 download Created with Sketch. 22.05KB
ATX Entitlement Offer Cleansing Statement
16/04/24 download Created with Sketch. 192.21KB
ATX Rights Issue Investor Slide Deck
16/04/24PRICE SENSITIVE download Created with Sketch. 5.96MB
ATX Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27
16/04/24PRICE SENSITIVE download Created with Sketch. 167.5KB
ATX Trading Halt
12/04/24PRICE SENSITIVE download Created with Sketch. 209.46KB
ATX AACR Conference Presentation
10/04/24 download Created with Sketch. 834.44KB
ATX Update on ACCENT Trial in Pancreatic Cancer
27/03/24PRICE SENSITIVE download Created with Sketch. 169.3KB
ATX Quarterly Activities/Appendix 4C Cash Flow Report
30/01/24PRICE SENSITIVE download Created with Sketch. 393.35KB
ATX FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
18/01/24PRICE SENSITIVE download Created with Sketch. 162.54KB
ATX Trading Halt
17/01/24PRICE SENSITIVE download Created with Sketch. 551.88KB
ATX Pause in Trading
17/01/24PRICE SENSITIVE download Created with Sketch. 114.79KB
ATX Amplia Reports First Patient Dosing In Phase 2a Accent Trial
17/01/24PRICE SENSITIVE download Created with Sketch. 169.03KB
ATX Change of Director's Interest Notice - Dr Warwick Tong
02/01/24 download Created with Sketch. 348.85KB
ATX Change of Director's Interest Notice - Dr Chris Burns
02/01/24 download Created with Sketch. 348KB
ATX Change of Director's Interest Notice - Dr Robert Peach
02/01/24 download Created with Sketch. 351.14KB
ATX Change of Director's Interest Notice - Jane Bell
02/01/24 download Created with Sketch. 323.98KB
ATX Notification of cessation of securities - ATX
02/01/24 download Created with Sketch. 21.65KB
ATX Application for quotation of securities - ATX
02/01/24 download Created with Sketch. 25.05KB
ATX Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea
04/12/23PRICE SENSITIVE download Created with Sketch. 166.59KB
ATX Appendix 4D and Financial Report Half Year ended 30 Sep 23
21/11/23PRICE SENSITIVE download Created with Sketch. 655.63KB
ATX Quarterly Activities/Appendix 4C Cash Flow Report
31/10/23PRICE SENSITIVE download Created with Sketch. 301.06KB
ATX Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
30/10/23PRICE SENSITIVE download Created with Sketch. 179.92KB
ATX Amplia Receives R&D Tax Rebate Totalling $ 2.4 Million
19/10/23PRICE SENSITIVE download Created with Sketch. 109.36KB
ATX AACR Ovarian Cancer Conference Presentation
09/10/23PRICE SENSITIVE download Created with Sketch. 5.12MB
ATX AACR Pancreatic Cancer Conference Presentation
29/09/23 download Created with Sketch. 14.3MB
ATX New Chief Financial Officer Mr Tim Luscombe
25/09/23 download Created with Sketch. 106.37KB
ATX Notification of cessation of securities - ATX
04/09/23 download Created with Sketch. 21.69KB
ATX Notification of cessation of securities - ATX
01/09/23 download Created with Sketch. 21.71KB
ATX Change of Director's Interest Notice - Dr Robert Peach
01/09/23 download Created with Sketch. 351.61KB
ATX Change of Director's Interest Notice - Dr Christopher Burns
29/08/23 download Created with Sketch. 351.31KB
ATX Notification regarding unquoted securities - ATX
29/08/23 download Created with Sketch. 29.02KB
ATX Results of Annual General Meeting
24/08/23 download Created with Sketch. 291.34KB
ATX CEO and MD Presentation to Annual General Meeting
24/08/23 download Created with Sketch. 2.87MB
ATX ACCENT Trial Recruitment Update
02/08/23 download Created with Sketch. 140.26KB
ATX ATX Quarterly Activities and Cashflow Reports - June 23 Qtr
31/07/23PRICE SENSITIVE download Created with Sketch. 307.66KB
ATX Notice of Annual General Meeting/Proxy Form
21/07/23 download Created with Sketch. 547.44KB
ATX ATX - Shareholder Newsletter July 2023
20/07/23 download Created with Sketch. 5.49MB
ATX Application for quotation of securities - ATX
12/07/23 download Created with Sketch. 24.84KB
ATX AMP945 International Nonproprietary Name Narmafotinib
21/06/23 download Created with Sketch. 104.84KB
ATX Amplia AGM to be held Thursday 24 August 2023
19/06/23 download Created with Sketch. 121.36KB
ATX Key to Corporate Governance Disclosures
31/05/23 download Created with Sketch. 292.87KB
ATX 2023 Corporate Governance Statement
30/05/23 download Created with Sketch. 418.65KB
ATX Annual Report to Shareholders
30/05/23PRICE SENSITIVE download Created with Sketch. 5.52MB
ATX AMP945 and FOLFIRINOX active in model of Pancreatic Cancer
29/05/23PRICE SENSITIVE download Created with Sketch. 197.6KB
ATX Grant to collaborate with CSIRO Supplementary Announcement
23/05/23PRICE SENSITIVE download Created with Sketch. 134.41KB
ATX Amplia receives grant to collaborate with CSIRO
22/05/23PRICE SENSITIVE download Created with Sketch. 130.74KB
ATX ACCENT Trial Recruitment Progress
09/05/23PRICE SENSITIVE download Created with Sketch. 161.79KB
ATX Quarterly Activities and Cashflow Reports - March 23 Qtr
26/04/23PRICE SENSITIVE download Created with Sketch. 275.01KB
ATX First Patient Recruited to Cohort 3 of ACCENT Trial
19/04/23PRICE SENSITIVE download Created with Sketch. 132.31KB
ATX Dose Escalation Approved in ACCENT Clinical Trial of AMP945
11/04/23PRICE SENSITIVE download Created with Sketch. 160.83KB
ATX ACCENT Trial Recruitment Progress
28/02/23PRICE SENSITIVE download Created with Sketch. 133.69KB
ATX ATX - US Conference Presentation
23/02/23 download Created with Sketch. 1.64MB
ATX AmpliaTherapeutics - Lorne Cancer Conference Presentation
09/02/23 download Created with Sketch. 713.45KB
ATX First Patient Recruited to Cohort 2 of Accent Trial
01/02/23PRICE SENSITIVE download Created with Sketch. 131.5KB
ATX Quarterly Activities and Cashflow Reports - December 2022
30/01/23PRICE SENSITIVE download Created with Sketch. 340.02KB
ATX Dose Escalation Approved in ACCENT Clinical Trial of AMP945
11/01/23PRICE SENSITIVE download Created with Sketch. 165.61KB
ATX Letter to Shareholders End of Year Summary and 2023 Plans
20/12/22PRICE SENSITIVE download Created with Sketch. 3.21MB
ATX Final Director's Interest Notice - Dr. John Lambert
01/12/22 download Created with Sketch. 375.23KB
ATX ACCENT Trial Recruitment Progress
29/11/22PRICE SENSITIVE download Created with Sketch. 103.3KB
ATX Appendix 4D and Financial Report Half Year ended 30 Sep 22
18/11/22PRICE SENSITIVE download Created with Sketch. 2.23MB
ATX Amplia Appoints Dr Christopher Burns CEO & Managing Director
07/11/22PRICE SENSITIVE download Created with Sketch. 132.58KB
ATX Quarterly Activities and Cashflow Reports - Sep 2022 Qtr
28/10/22PRICE SENSITIVE download Created with Sketch. 503.17KB
ATX Notification regarding unquoted securities - ATX
10/10/22 download Created with Sketch. 28.37KB
ATX AMP886 Activity in Acute Myeloid Leukemia
03/10/22PRICE SENSITIVE download Created with Sketch. 238.68KB
ATX AACR Conference Presentation
14/09/22 download Created with Sketch. 848.81KB
ATX CEO Resignation
12/09/22PRICE SENSITIVE download Created with Sketch. 103.1KB
ATX Notification regarding unquoted securities - ATX
07/09/22 download Created with Sketch. 29.46KB
ATX Change of Director's Interest Notice - Dr. Warwick Tong
07/09/22 download Created with Sketch. 347.59KB
ATX Change of Director's Interest Notice - Dr. Robert Peach
07/09/22 download Created with Sketch. 350.91KB
ATX Change of Director's Interest Notice - Dr. Christopher Burns
07/09/22 download Created with Sketch. 346.2KB
ATX Change of Director's Interest Notice - Mrs. Jane Bell
07/09/22 download Created with Sketch. 285.71KB
ATX Change of Director's Interest Notice - Dr. John Lambert
06/09/22 download Created with Sketch. 365.18KB
ATX Notification of cessation of securities - ATX
02/09/22 download Created with Sketch. 21.68KB
ATX Amplia Receives $1.8m R&D Tax Incentive
31/08/22PRICE SENSITIVE download Created with Sketch. 104.17KB
ATX Results of Annual General Meeting
25/08/22 download Created with Sketch. 341.43KB
ATX CEO & Managing Director Presentation to AGM
25/08/22PRICE SENSITIVE download Created with Sketch. 5.94MB
ATX Annual General Meeting - ESOP and New Constitution
17/08/22 download Created with Sketch. 165.68KB
ATX Employee Security Ownership Plan
17/08/22 download Created with Sketch. 382.88KB
ATX Change of Director's Interest Notice - Dr. Warwick Tong
04/08/22 download Created with Sketch. 345.52KB
ATX First Patient Recruited to ACCENT Trial in Pancreatic Cancer
02/08/22PRICE SENSITIVE download Created with Sketch. 132.49KB
ATX Quarterly Activities and Cashflow Reports - June 2022 Qtr
28/07/22PRICE SENSITIVE download Created with Sketch. 371.69KB
ATX Presentation at Major Pancreatic Cancer Conference
25/07/22 download Created with Sketch. 153.78KB
ATX Notice of Annual General Meeting/Proxy - YE 31 March 2022
22/07/22 download Created with Sketch. 591.2KB
ATX Change of Director's Interest Notice - Dr. Chistopher Burns
07/07/22 download Created with Sketch. 341.79KB
ATX Change of Director's Interest Notice - Dr. Robert Peach
07/07/22 download Created with Sketch. 276.74KB
ATX Change of Director's Interest Notice - Dr. John Lambert
07/07/22 download Created with Sketch. 467.75KB
ATX Change of Director's Interest Notice - Dr. Warwick Tong
07/07/22 download Created with Sketch. 402.32KB
ATX Notification of cessation of securities - ATX
05/07/22 download Created with Sketch. 21.69KB
ATX Application for quotation of securities - ATX
30/06/22 download Created with Sketch. 24.91KB
ATX Annual General Meeting to be held Thursday 25 August 2022
29/06/22 download Created with Sketch. 118.42KB
ATX Registered Office and Principal Place of Business
24/06/22 download Created with Sketch. 127.54KB
ATX Notification of Expiry of Unlisted Options
09/06/22 download Created with Sketch. 210.42KB
ATX Application for quotation of securities - ATX
09/06/22 download Created with Sketch. 24.91KB
ATX AMP945 Shows Efficacy in Model of Lung Fibrosis
02/06/22PRICE SENSITIVE download Created with Sketch. 182.84KB
ATX App 4G - Key to Corporate Governance Disclosures
30/05/22 download Created with Sketch. 368.09KB
ATX 2022 Corporate Governance Statement
30/05/22 download Created with Sketch. 396.46KB
ATX Preliminary Final Report and Annual Report YE 31 March 2022
30/05/22PRICE SENSITIVE download Created with Sketch. 2.92MB
ATX Amplia Receives Second Ethics Clearance for Phase 2 Trial
13/05/22PRICE SENSITIVE download Created with Sketch. 158.42KB
(20min delay)
Last
6.2¢
Change
0.000(0.00%)
Mkt cap ! $12.02M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 150000 6.1¢
 

Sellers (Offers)

Price($) Vol. No.
6.2¢ 180369 2
View Market Depth
Last trade - 16.12pm 03/05/2024 (20 minute delay) ?
ATX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.